Immune checkpoint inhibitors are now a cornerstone of treatment for non-small cell lung cancer (NSCLC). Tissue-based assays, such as Programmed cell death protein 1 (PD-L1) expression or mismatch repair deficiency/microsatellite instability (MMRD/MSI) status, are approved as treatment drivers in var …

Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer / B, Duchemann; J, Remon; M, Naigeon; L, Mezquita; Ferrara, R; L, Cassard; Jm, Jouniaux; L, Boselli; J, Grivel; E, Auclin; A, Desnoyer; B, Besse; N, Chaput. - In: CANCERS. - ISSN 2072-6694. - 9:5(2020), pp. 1143-1161. [10.3390/cancers12123625]

Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer

FERRARA R;
2020-01-01

Abstract

Immune checkpoint inhibitors are now a cornerstone of treatment for non-small cell lung cancer (NSCLC). Tissue-based assays, such as Programmed cell death protein 1 (PD-L1) expression or mismatch repair deficiency/microsatellite instability (MMRD/MSI) status, are approved as treatment drivers in var …
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/176357
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 33
  • ???jsp.display-item.citation.isi??? 30
social impact